CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 213 enrolled
Drug / intervention
PA21 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01850602
NCT01850602Phase 3Completed
CompareCT.gov

A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

Kissei Pharmaceutical Co., Ltd.·interventional·Posted May 9, 2013·Updated Oct 9, 2018

In Brief

A Phase 3 clinical trial evaluating PA21 and Sevelamer hydrochloride for Hemodialysis and Hyperphosphatemia. Completed, enrolled 213 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of PA21 in hemodialysis patients with hyperphosphatemia

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHemodialysis, Hyperphosphatemia
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 9, 2013
Enrollment StartApr 23, 2013
Primary CompletionDec 1, 2013
Study CompletionDec 10, 2013
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 13.1 years ago

Interventions

PA21drug

Sevelamer hydrochloridedrug